Previous 10 | Next 10 |
- Treatment with TMB-001 demonstrated greater proportions of participants achieving primary and key secondary endpoints versus vehicle regardless of the subtype of congenital ichthyosis - BASKING RIDGE, NJ, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceutical...
TEGNA TGNA -22% after FCC orders hearing for Standard General sale . Mount Rainier Acquisition RNER -15% on FY earnings release . Ready Capital RC -12% on Q4 earnings release . Atlas Lithium ( ATLX ) -11% . Movella ( MVLA ) -10% . Ambrx ...
3 Tips for Building a Long Term Penny Stock Portfolio Building a penny stocks portfolio can be a smart strategy for investors who are willing to take on a higher level of risk in exchange for the potential for higher returns. While penny stocks can be volatile and risky, they can also off...
3 Tips for Analyzing Stock Market Conditions to Make Money With Penny Stocks Analyzing market conditions is a crucial factor in making money with penny stocks. Market conditions can influence the performance of penny stocks and affect their potential for significant gains or losses. There...
The European Commission has granted orphan drug designation to TMB-001, a phase 1 candidate from Timber Pharmaceuticals ( NYSE: TMBR ) for X-linked recessive ichthyosis (XLRI), a rare genetic skin disorder. The stock is up 46% in Friday afternoon trading. TMB-001 is topical is...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Timber Pharmaceuticals (NYSEMKT: TMBR ) stock is taking off on Friday after getting an orphan drug designation in Europe. That comes from the EC and covers TMB-001 for the treatment of ...
Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ, Feb. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a c...
Virtual Business Briefing With Q&A to be Webcast on December 20, 2022 at 10:30 am ET BASKING RIDGE, NJ - ( NewMediaWire ) - December 14, 2022 - Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused...
BASKING RIDGE, NJ, Dec. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare an...
Timber Pharmaceuticals press release ( NYSE: TMBR ): Q3 GAAP EPS of -$1.52. Timber ended the third quarter with approximately $11.2 million in cash and 2.7 million shares of common stock outstanding after giving retroactive effect to a 1-for-50 reverse split of its shares ...
News, Short Squeeze, Breakout and More Instantly...
Timber Pharmaceuticals Inc. Company Name:
TMBR Stock Symbol:
NYSE Market:
WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that...
WARREN, NJ - ( NewMediaWire ) - November 28, 2023 - Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-...
WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated d...